PMID- 30619371
OWN - NLM
STAT- MEDLINE
DCOM- 20191025
LR  - 20200309
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 9
DP  - 2018
TI  - Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating 
      Graft-Versus-Host Disease.
PG  - 3041
LID - 10.3389/fimmu.2018.03041 [doi]
LID - 3041
AB  - Allogeneic stem cell transplantation (allo-SCT) is a curable method for the 
      treatment of hematological malignancies. In the past two decades, the 
      establishment of haploidentical transplant modalities make "everyone has a donor" 
      become a reality. However, graft-versus-host disease (GVHD) and relapse remain 
      the major two causes of death either in the human leukocyte antigen (HLA)-matched 
      transplant or haploidentical transplant settings, both of which restrict the 
      improvement of transplant outcomes. Preclinical mice model showed that both 
      donor-derived T cells and natural killer (NK) cells play important role in the 
      pathogenesis of GVHD and the effects of graft-versus-leukemia (GVL). Hence, 
      understanding the immune mechanisms of GVHD and GVL would provide potential 
      strategies for the control of leukemia relapse without aggravating GVHD. The 
      purpose of the current review is to summarize the biology of GVHD and GVL 
      responses in preclinical models and to discuss potential novel therapeutic 
      strategies to reduce the relapse rate after allo-SCT. We will also review the 
      approaches, including optimal donor selection and, conditioning regimens, donor 
      lymphocyte infusion, BCR/ABL-specific CTL, and chimeric antigen receptor-modified 
      T cells, which have been successfully used in the clinic to enhance and preserve 
      anti-leukemia activity, especially GVL effects, without aggravating GVHD or 
      alleviate GVHD.
FAU - Chang, Ying-Jun
AU  - Chang YJ
AD  - Peking University People's Hospital & Peking University Institute of Hematology, 
      Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, 
      China.
FAU - Zhao, Xiang-Yu
AU  - Zhao XY
AD  - Peking University People's Hospital & Peking University Institute of Hematology, 
      Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, 
      China.
FAU - Huang, Xiao-Jun
AU  - Huang XJ
AD  - Peking University People's Hospital & Peking University Institute of Hematology, 
      Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, 
      China.
AD  - Peking-Tsinghua Center for Life Sciences, Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20181221
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Immunologic Factors)
RN  - 0 (Receptors, Chimeric Antigen)
SB  - IM
MH  - Allografts/drug effects/immunology
MH  - Animals
MH  - Clinical Trials as Topic
MH  - Disease Models, Animal
MH  - Donor Selection
MH  - Graft vs Host Disease/immunology/prevention & control
MH  - Graft vs Leukemia Effect/*immunology
MH  - Hematopoietic Stem Cell Transplantation/*adverse effects
MH  - Humans
MH  - Immunologic Factors/administration & dosage
MH  - Immunotherapy, Adoptive/*methods
MH  - Killer Cells, Natural/immunology
MH  - Leukemia/immunology/pathology/*therapy
MH  - Mice
MH  - Neoplasm Recurrence, Local/immunology/prevention & control
MH  - Receptors, Chimeric Antigen/immunology
MH  - T-Lymphocytes/immunology/transplantation
MH  - Transplantation Conditioning/*methods
MH  - Transplantation, Homologous/adverse effects
PMC - PMC6308132
OTO - NOTNLM
OT  - G-CSF
OT  - allogeneic stem cell transplantation
OT  - graft-versus-host disease
OT  - graft-versus-leukemia
OT  - relapse
EDAT- 2019/01/09 06:00
MHDA- 2019/10/28 06:00
PMCR- 2018/01/01
CRDT- 2019/01/09 06:00
PHST- 2018/10/01 00:00 [received]
PHST- 2018/12/10 00:00 [accepted]
PHST- 2019/01/09 06:00 [entrez]
PHST- 2019/01/09 06:00 [pubmed]
PHST- 2019/10/28 06:00 [medline]
PHST- 2018/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2018.03041 [doi]
PST - epublish
SO  - Front Immunol. 2018 Dec 21;9:3041. doi: 10.3389/fimmu.2018.03041. eCollection 
      2018.